Table Info

Table 4.

Ongoing clinical trials under study involving nanomaterials for skin cancer

Trial No.	Nanomaterial under study	Condition	Phase	Status	References
NCT00004104	Liposome/interferon alfa-2b and melanoma vaccine	Melanoma	Phase 2	Completed	[166]
NCT00081042	Albumin-nanoparticle/paclitaxel (ABI-007)	Melanoma	Phase 2	Completed	[167]
NCT00145041	Liposome/vincristine	Melanoma	Phase 1	Completed	[168]
NCT00626405	Albumin nanoparticle/paclitaxel	Melanoma	Phase 2	Completed	[169]
NCT01300533	Nanoparticle/docetaxel (BIND-014)	Skin cancer	Phase 1	Completed	[170]
NCT02158520	Albumin nanoparticle/paclitaxel (Abraxane®)	Melanoma	Phase 2	Completed	[171]
NCT03101358	Topical nanoparticle ointment/paclitaxel (SOR007)	Cutaneous metastases from non-melanoma cancer	Phase 1 and 2	Completed	[172]

Declarations

Acknowledgments

Authors would like to offer special thanks to MM College of Pharmacy, Amity institute of Nanotechnology for allowing carrying out this work and other research projects.

Author contributions

RG, SH, and KW: Writing—original draft, Writing—review & editing, Visualization. HC: Supervision, Investigation, Conceptualization, Writing—review & editing. RP: Formal analysis, Resources, Visualization. ML and RS: Writing—review & editing, Supervision, Methodology. All the authors have equally contributed to conceiving this paper and participated in its revisions. All authors read and approved the final manuscript.

Conflicts of interest

The authors have no relevant conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Matta Reddy A, Iqbal M, Chopra H, Urmi S, Junapudi S, Bibi S, et al. Pivotal role of vitamin D in mitochondrial health, cardiac function, and human reproduction. EXCLI J. 2022;21:967–90. [DOI] [PubMed] [PMC]

Skin cancer statistics [Internet]. London: World Cancer Research Fund International; [cited 2023 Apr 4]. Available from: https://www.wcrf.org/cancer-trends/skin-cancer-statistics/

Skin Cancer [Internet]. Boston (MA): Dana-Farber Cancer Institute; [cited 2023 Apr 4]. Available from: https://www.dana-farber.org/skin-cancer/

Shi FT, Yu M, Zloty D, Bell RH, Wang E, Akhoundsadegh N, et al. Notch signaling is significantly suppressed in basal cell carcinomas and activation induces basal cell carcinoma cell apoptosis. Mol Med Rep. 2017;15:1441–54. [DOI] [PubMed] [PMC]

Carballo GB, Honorato JR, de Lopes GPF, Spohr TCLSE. A highlight ofSonic hedgehog pathway. Cell Commun Signal. 2018;16:11. [DOI] [PubMed] [PMC]

Pak E, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev Cell. 2016;38:333–44. [DOI] [PubMed] [PMC]

Murone M, Rosenthal A, de Sauvage FJ. Sonic hedgehog signaling by the Patched–Smoothened receptor complex. Curr Biol. 1999;9:76–84. [DOI] [PubMed]

Choudhry Z, Rikani AA, Choudhry AM, Tariq S, Zakaria F, Asghar MW, et al. Sonic hedgehog signalling pathway: a complex network. Ann Neurosci. 2014;21:28–31. [DOI] [PubMed] [PMC]

Arensdorf AM, Marada S, Ogden SK. Smoothened regulation: a tale of two signals. Trends Pharmacol Sci. 2016;37:62–72. [DOI] [PubMed] [PMC]

10.

Roberts B, Casillas C, Alfaro AC, Jägers C, Roelink H. Patched1 and Patched2 inhibit Smoothened non-cell autonomously. Elife. 2016;5:e17634. [DOI] [PubMed] [PMC]

11.

Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27:342–53. [DOI] [PubMed] [PMC]

12.

Fan W, Rokohl AC, Guo Y, Chen H, Gao T, Kakkassery V, et al. Narrative review: mechanism of ultraviolet radiation-induced basal cell carcinoma. Front Oral Maxillofac Med. 2023;5:9. [DOI]

13.

Abidi A. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian J Pharmacol. 2014;46:3–12. [DOI] [PubMed] [PMC]

14.

Ouhtit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, Yamasaki H, et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst. 1998;90:523–31. [DOI] [PubMed]

15.

Chial H. Tumor suppressor (TS) genes and the two-hit hypothesis. Nat Educ. 2008;1:177.

16.

*191170 [Internet]. Baltimore (MD): Johns Hopkins University; [cited 2023 Apr 6]. Available from: https://omim.org/entry/191170

17.

Shah DJ, Sachs RK, Wilson DJ. Radiation-induced cancer: a modern view. Br J Radiol. 2012;85:e1166–73. [DOI] [PubMed] [PMC]

18.

Oncogenes, tumor suppressor genes, and DNA repair genes [Internet]. New York (NY): American Cancer Society; c2023 [cited 2023 Apr 6]. Available from: https://www.cancer.org/cancer/understanding-cancer/genes-and-cancer/oncogenes-tumor-suppressor-genes.html

19.

D’Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci. 2013;14:12222–48. [DOI] [PubMed] [PMC]

20.

Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. In: Reichrath J, editor. Sunlight, vitamin D and skin cancer. New York: Springer; 2008. pp. 162–78. [DOI] [PubMed]

21.

Li Z, Pearlman AH, Hsieh P. DNA mismatch repair and the DNA damage response. DNA Repair (Amst). 2016;38:94–101. [DOI] [PubMed] [PMC]

22.

Young LC, Listgarten J, Trotter MJ, Andrew SE, Tron VA. Evidence that dysregulated DNA mismatch repair characterizes human nonmelanoma skin cancer. Br J Dermatol. 2008;158:59–69. [DOI] [PubMed]

23.

Kasumagic-Halilovic E, Hasic M, Ovcina-Kurtovic N. A clinical study of basal cell carcinoma. Med Arch. 2019;73:394–8. [DOI] [PubMed] [PMC]

24.

Teng Y, Yu Y, Li S, Huang Y, Xu D, Tao X, et al. Ultraviolet radiation and basal cell carcinoma: an environmental perspective. Front Public Health. 2021;9:666528. [DOI] [PubMed] [PMC]

25.

Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol. 2005;124:505–13. [DOI] [PubMed]

26.

Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23:389–402. [DOI] [PubMed]

27.

Centers for Disease Control and Prevention (CDC). Sunburn prevalence among adults---United States, 1999, 2003, and 2004. MMWR Morb Mortal Wkly Rep. 2007;56:524–8. [PubMed]

28.

Benjamin CL, Ananthaswamy HN. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol. 2007;224:241–8. [DOI] [PubMed] [PMC]

29.

Zhang H, Ping XL, Lee PK, Wu XL, Yao YJ, Zhang MJ, et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol. 2001;158:381–5. [DOI] [PubMed] [PMC]

30.

Chung JH, Bunz F. A loss-of-function mutation in PTCH1 suggests a role for autocrine hedgehog signaling in colorectal tumorigenesis. Oncotarget. 2013;4:2208–11. [DOI] [PubMed] [PMC]

31.

Frisch M, Hjalgrim H, Olsen JH, Melbye M. Risk for subsequent cancer after diagnosis of basal-cell carcinoma:a population-based, epidemiologic study. Ann Intern Med. 1996;125:815–21. [DOI] [PubMed]

32.

Brin L, Zubair AS, Brewer JD. Optimal management of skin cancer in immunosuppressed patients. Am J Clin Dermatol. 2014;15:339–56. [DOI] [PubMed]

33.

Organ transplant and skin cancer risk [Internet]. Oakland (CA): The Regents of The University of California; c2023 [cited 2023 Apr 7]. Available from: https://www.ucsfhealth.org/education/organ-transplant-and-skin-cancer-risk

34.

Hao X, Lai W, Xia X, Xu J, Wu Y, Lv C, et al. Skin cancer outcomes and risk factors in renal transplant recipients: analysis of organ procurement and transplantation network data from 2000 to 2021. Front Oncol. 2022;12:1017498. [DOI] [PubMed] [PMC]

35.

Psaty EL, Halpern AC. Current and emerging technologies in melanoma diagnosis: the state of the art. Clin Dermatol. 2009;27:35–45. [DOI] [PubMed] [PMC]

36.

Excisional and incisional biopsy [Internet]. Stanford (CA): Stanford HealthCare; c2023 [cited 2023 Apr 7]. Available from: https://stanfordhealthcare.org/medical-tests/b/biopsy/types/excisional-incisional-biopsy.html

37.

Beard CJ, Ponnarasu S, Schmieder GJ. Excisional biopsy. Treasure Island: StatPearls Publishing; 2022.

38.

Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatol Online J. 2013;4:12–7. [DOI] [PubMed] [PMC]

39.

Chakrabarty B, Sharma MC, Gulati S, Kabra M, Pandey RM, Sarkar C. Skin biopsy: a new tool to diagnose sarcoglycanopathy. J Child Neurol. 2014;29:NP5–8. [DOI] [PubMed]

40.

Al-Abbadi MA. Basics of cytology. Avicenna J Med. 2011;1:18–28. [DOI] [PubMed] [PMC]

41.

Barton K, Curling OM, Paridaens AD, Hungerford JL. The role of cytology in the diagnosis of periocular basal cell carcinomas. Ophthalmic Plast Reconstr Surg. 1996;12:190–5. [DOI] [PubMed]

42.

Basal cell carcinoma workup [Internet]. New York (NY): WebMD; c1994–2023 [cited 2023 Apr 7]. Available from: https://emedicine.medscape.com/article/276624-workup#c9

43.

Mannor GE, Wardell K, Wolfley DE, Nilsson GE. Laser Doppler perfusion imaging of eyelid skin. Ophthalmic Plast Reconstr Surg. 1996;12:178–85. [DOI] [PubMed]

44.

Takiddin A, Schneider J, Yang Y, Abd-Alrazaq A, Househ M. Artificial intelligence for skin cancer detection: scoping review. J Med Internet Res. 2021;23:e22934. [DOI] [PubMed] [PMC]

45.

An artificial intelligence tool that can help detect melanoma [Internet]. Cambridge (MA): Massachusetts Institute of Technology; [cited 2023 Jun 30]. Available from: https://news.mit.edu/2021/artificial-intelligence-tool-can-help-detect-melanoma-0402

46.

Smak Gregoor AM, Sangers TE, Bakker LJ, Hollestein L, Uyl-de Groot CA, Nijsten T, et al. An artificial intelligence based app for skin cancer detection evaluated in a population based setting. NPJ Digit Med. 2023;6:90. [DOI] [PubMed] [PMC]

47.

Kränke T, Tripolt-Droschl K, Röd L, Hofmann-Wellenhof R, Koppitz M, Tripolt M. New AI-algorithms on smartphones to detect skin cancer in a clinical setting—a validation study. PLoS One. 2023;18:e0280670. [DOI] [PubMed] [PMC]

48.

Soenksen LR, Kassis T, Conover ST, Marti-Fuster B, Birkenfeld JS, Tucker-Schwartz J, et al. Using deep learning for dermatologist-level detection of suspicious pigmented skin lesions from wide-field images. Sci Transl Med. 2021;13:eabb3652. [DOI] [PubMed]

49.

Artificial intelligence & melanoma detection: closing the gaps [Internet]. Washington, D.C.: Melanoma Research Alliance; [cited 2023 Jun 30]. Available from: https://www.curemelanoma.org/blog/article/artificial-intelligence-and-melanoma-detection-closing-the-gaps

50.

Prieto-Granada C, Rodriguez-Waitkus P. Basal cell carcinoma: epidemiology, clinical and histologic features, and basic science overview. Curr Probl Cancer. 2015;39:198–205. [DOI] [PubMed]

51.

Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145:1431–8. [DOI] [PubMed]

52.

Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722–33. [DOI] [PubMed]

53.

Bubna AK. Imiquimod-its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47:354–9. [DOI] [PubMed] [PMC]

54.

Ou-Yang Y, Zheng Y, Mills KE. Photodynamic therapy for skin carcinomas: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1089361. [DOI] [PubMed] [PMC]

55.

Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017;56:2543–57. [DOI] [PubMed] [PMC]

56.

Dessinioti C, Plaka M, Soura E, Mortaki D, Papaxoinis G, Gogas H, et al. A practical guide for the follow-up of patients with advanced basal cell carcinoma during treatment with hedgehog pathway inhibitors. Oncologist. 2019;24:e755–64. [DOI] [PubMed] [PMC]

57.

Nix NM, Burdine O, Walker M. Vismodegib: first-in-class hedgehog pathway inhibitor for metastatic or locally advanced basal cell carcinoma. J Adv Pract Oncol. 2014;5:294–6. [DOI] [PubMed] [PMC]

58.

Fellner C. Vismodegib (erivedge) for advanced basal cell carcinoma. P T. 2012;37:670–82. [PubMed] [PMC]

59.

Casey D, Demko S, Shord S, Zhao H, Chen H, He K, et al. FDA approval summary: sonidegib for locally advanced basal cell carcinoma. Clin Cancer Res. 2017;23:2377–81. [DOI] [PubMed]

60.

FDA approves sonidegib for some patients with advanced basal cell carcinoma [Internet]. Rockville (MD): National Cancer Institute; [cited 2023 Apr 10]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2015/sonidegib-bcc

61.

Ally MS, Ransohoff K, Sarin K, Atwood SX, Rezaee M, Bailey-Healy I, et al. Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatol. 2016;152:452–6. [DOI] [PubMed] [PMC]

62.

Davis CM, Lewis KD. Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again. Ther Adv Med Oncol. 2022;14:17588359211066147. [DOI] [PubMed] [PMC]

63.

Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433–40. [PubMed]

64.

Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol. 2006;54:1033–8. [DOI] [PubMed]

65.

Chimenti S, Peris K, Di Cristofaro S, Fargnoli MC, Torlone G. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology. 1995;190:214–7. [DOI] [PubMed]

66.

Fernandez-Martori M, Bello-Rivero I, Duncan-Roberts Y. Treatment of basal cell carcinoma with interferons alpha-2b and gamma in primary care. MEDICC Rev. 2018;20:11. [DOI] [PubMed]

67.

Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 1986;15:437–43. [DOI] [PubMed]

68.

Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47:390–8. [DOI] [PubMed]

69.

Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57:616–21. [DOI] [PubMed]

70.

Stockfleth E, Ulrich C, Hauschild A, Lischner S, Meyer T, Christophers E. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12:569–72. [PubMed]

71.

Berman B. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J Drugs Dermatol. 2008;7 Suppl 1:s3–6. [PubMed]

72.

Arits AHMM, Mosterd K, Essers BAB, Spoorenberg E, Sommer A, De Rooij MJM, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647–54. [DOI] [PubMed]

73.

Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–56. [DOI] [PubMed]

74.

Torres-Gómez FJ,Torres Olivera FJ,Torres Gómez A. Keloidal basal cell carcinoma. Med Cutan Ibero Lat Am. 2015;43:153–5. Spanish.

75.

Lewis JE. Keloidal basal cell carcinoma. Am J Dermatopathol. 2007;29:485. [DOI] [PubMed]

76.

Misago N, Ogusu Y, Narisawa Y. Keloidal basal cell carcinoma after radiation therapy. Eur J Dermatol. 2004;14:182–5. [PubMed]

77.

Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67:1235–41. [DOI] [PubMed]

78.

Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119:1994–9. [DOI] [PubMed]

79.

Piccinno R, Benardon S, Gaiani FM, Rozza M, Caccialanza M. Dermatologic radiotherapy in the treatment of extensive basal cell carcinomas: a retrospective study. J Dermatolog Treat. 2017;28:426–30. [DOI] [PubMed]

80.

Morton CA, McKenna KE, Rhodes LE; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–66. [DOI] [PubMed]

81.

Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol. 2007;56:125–43.

82.

Calzavara-Pinton PG, Szeimies RM, Ortel B, Zane C. Photodynamic therapy with systemic administration of photosensitizers in dermatology. J Photochem Photobiol B. 1996;36:225–31. [DOI] [PubMed]

83.

Puccioni M, Santoro N, Giansanti F, Ucci F, Rossi R, Lotti T, et al. Photodynamic therapy using methyl aminolevulinate acid in eyelid basal cell carcinoma: a 5-year follow-up study. Ophthalmic Plast Reconstr Surg. 2009;25:115–8. [DOI] [PubMed]

84.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164–72. [DOI] [PubMed]

85.

MedWatch: the FDA safety information and adverse event reporting program [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [cited 2023 Apr 11]. Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

86.

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–28. [DOI] [PubMed]

87.

FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [cited 2023 Apr 11]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma

88.

Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12:4669–84. [DOI] [PubMed]

89.

Manjappa AS, Kumbhar PS, Patil AB, Disouza JI, Patravale VB. Polymeric mixed micelles: improving the anticancer efficacy of single-copolymer micelles. Crit Rev Ther Drug Carrier Syst. 2019;36:1–58. [DOI] [PubMed]

90.

Mehan N, Kumar M, Bhatt S, Shankar R, Kumari B, Pahwa R, et al. Self-assembly polymeric nano micelles for the futuristic treatment of skin cancer and phototoxicity: therapeutic and clinical advancement. Crit Rev Ther Drug Carrier Syst. 2022;39:79–95. [DOI] [PubMed]

91.

Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11:2989–3001. [DOI] [PubMed]

92.

Varshosaz J, Taymouri S, Hassanzadeh F, Javanmard SH, Rostami M. Self-assembly micelles with lipid core of cholesterol for docetaxel delivery to B16F10 melanoma and HepG2 cells. J Liposome Res. 2015;25:157–65. [DOI] [PubMed]

93.

Velluto D, Thomas SN, Simeoni E, Swartz MA, Hubbell JA. PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: tumor immunotoxicity in B16F10 melanoma. Biomaterials. 2011;32:9839–47. [DOI] [PubMed]

94.

Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752–6. [PubMed]

95.

Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Skin penetration and distribution of polymeric nanoparticles. J Control Release. 2004;99:53–62. [DOI] [PubMed]

96.

Chopra H, Singh I, Kumar S, Bhattacharya T, Rahman MH, Akter R, et al. A comprehensive review on hydrogels. Curr Drug Deliv. 2022;19:658–75. [DOI] [PubMed]

97.

Chopra H, Kumar S, Singh I. Bioadhesive hydrogels and their applications. In: Mittal KL, Bakshi IS, Narang JK, editors. Bioadhesives in drug delivery. Beverly: Scrivener Publishing; 2020. pp. 147–70.

98.

Chopra H, Bibi S, Kumar S, Khan MS, Kumar P, Singh I. Preparation and evaluation of chitosan/PVA based hydrogel films loaded with honey for wound healing application. Gels. 2022;8:111. [DOI] [PubMed] [PMC]

99.

Devi L, Gaba P, Chopra H. Tailormade drug delivery system: a novel trio concept of 3DP+ hydrogel+ SLA. J Drug Deliv Ther. 2019;9:861–6. [DOI]

100.

Chopra H, Kumar S, Singh I. Bioinks for 3D printing of artificial extracellular matrices. In: du Toit LC, Kumar P, Choonara YE, Pillay V, editors. Advanced 3D-printed systems and nanosystems for drug delivery and tissue engineering. Cambridge: Woodhead Publishing; 2020. pp. 1–37.

101.

Chopra H, Kumar S, Singh I. Biopolymer-based scaffolds for tissue engineering applications. Curr Drug Targets. 2021;22:282–95. [DOI] [PubMed]

102.

Chopra H, Kumar S, Singh I. Strategies and therapies for wound healing: a review. Curr Drug Targets. 2022;23:87–98. [DOI] [PubMed]

103.

Pandey P, Chopra H, Kaushik D, Verma R, Purohit D, Parashar J, et al. Multifunctional patented nanotherapeutics for cancer intervention: 2010-onwards. Recent Pat Anticancer Drug Discov. 2023;18:38–52. [DOI] [PubMed]

104.

Gonsalves A, Tambe P, Le D, Thakore D, Wadajkar AS, Yang J, et al. Synthesis and characterization of a novel pH-responsive drug-releasing nanocomposite hydrogel for skin cancer therapy and wound healing. J Mater Chem B. 2021;9:9533–46. [DOI] [PubMed] [PMC]

105.

Sepantafar M, Maheronnaghsh R, Mohammadi H, Radmanesh F, Hasani-Sadrabadi MM, Ebrahimi M, et al. Engineered hydrogels in cancer therapy and diagnosis. Trends Biotechnol. 2017;35:1074–87. [DOI] [PubMed]

106.

Highton AJ, Kojarunchitt T, Girardin A, Hook S, Kemp RA. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunol Cell Biol. 2015;93:634–40. [DOI] [PubMed]

107.

Tokuda EY, Leight JL, Anseth KS. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Biomaterials. 2014;35:4310–8. [DOI] [PubMed] [PMC]

108.

Tokuda EY, Jones CE, Anseth KS. PEG–peptide hydrogels reveal differential effects of matrix microenvironmental cues on melanoma drug sensitivity. Integr Biol (Camb). 2017;9:76–87. [DOI] [PubMed] [PMC]

109.

Lu JW, Miao Y, Guo CX, Ke QF, Yin JH, Zhou SM, et al. Lanthanum-doped chitosan hydrogels promote the apoptosis of melanoma cells by Bcl-2/Bax pathway. ACS Appl Bio Mater. 2018;1:1468–77. [DOI] [PubMed]

110.

Liu J, Qi C, Tao K, Zhang J, Zhang J, Xu L, et al. Sericin/dextran injectable hydrogel as an optically trackable drug delivery system for malignant melanoma treatment. ACS Appl Mater Interfaces. 2016;8:6411–22. [DOI] [PubMed]

111.

Jiang T, Wang T, Li T, Ma Y, Shen S, He B, et al. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS Nano. 2018;12:9693–701. [DOI] [PubMed]

112.

Shubayev VI, Pisanic TR II, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61:467–77. [DOI] [PubMed] [PMC]

113.

Amin RM, Abdelmonem A, Verwanger T, Elsherbini E, Krammer B. Cytotoxicity of magnetic nanoparticles on normal and malignant human skin cells. Nano Life. 2014;4:1440002. [DOI]

114.

Alromi DA, Madani SY, Seifalian A. Emerging application of magnetic nanoparticles for diagnosis and treatment of cancer. Polymers (Basel). 2021;13:4146. [DOI] [PubMed] [PMC]

115.

Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol. 2011;35:147–51. [PubMed]

116.

Weischer M, Blum A, Eberhard F, Röcken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol. 2004;84:370–4. [DOI] [PubMed]

117.

Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14:6414–35. [DOI] [PubMed] [PMC]

118.

Shi H, Sadler PJ. How promising is phototherapy for cancer? Br J Cancer. 2020;123:871–3. [DOI] [PubMed] [PMC]

119.

Liu Z, Lu Y, Lebwohl M, Wei H. PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2’-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radic Biol Med. 1999;27:127–33. [DOI] [PubMed]

120.

Hunzeker CM, Geronemus RG. Treatment of superficial infantile hemangiomas of the eyelid using the 595-nm pulsed dye laser. Dermatol Surg. 2010;36:590–7. [DOI] [PubMed]

121.

Lange C, Lehmann C, Mahler M, Bednarski PJ. Comparison of cellular death pathways after mTHPC-mediated photodynamic therapy (PDT) in five human cancer cell lines. Cancers (Basel). 2019;11:702. [DOI] [PubMed] [PMC]

122.

Vrielink OM, Kruijff S, van Leeuwen BL, Roodenburg JL. Application of CO₂ laser evaporation in locally advanced melanoma. Melanoma Manag. 2019;6:MMT14. [DOI] [PubMed] [PMC]

123.

Benson TA, Hibler BP, Kotliar D, Avram M. Nonablative fractional laser treatment is associated with a decreased risk of subsequent facial keratinocyte carcinoma development. Dermatol Surg. 2023;49:149–54. [DOI] [PubMed]

124.

Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112:1515–21. [DOI] [PubMed] [PMC]

125.

Chopra H, Dey PS, Das D, Bhattacharya T, Shah M, Mubin S, et al. Curcumin nanoparticles as promising therapeutic agents for drug targets. Molecules. 2021;26:4998. [DOI] [PubMed] [PMC]

126.

Bhattacharya T, Das D, Borges e Soares GA, Chakrabarti P, Ai Z, Chopra H, et al. Novel green approaches for the preparation of gold nanoparticles and their promising potential in oncology. Processes. 2022;10:426. [DOI]

127.

DeLouise LA. Applications of nanotechnology in dermatology. J Invest Dermatol. 2012;132:964–75. [DOI] [PubMed] [PMC]

128.

Husain S, Verma SK, Yasin D, Hemlata, A Rizvi MM, Fatma T. Facile green bio-fabricated silver nanoparticles from Microchaete infer dose-dependent antioxidant and anti-proliferative activity to mediate cellular apoptosis. Bioorg Chem. 2021;107:104535. [DOI] [PubMed]

129.

Saindane D, Bhattacharya S, Shah R, Prajapati BG. The recent development of topical nanoparticles for annihilating skin cancer. All Life. 2022;15:843–69. [DOI]

130.

Patravale VB, Desai PP. Topical nanointerventions for therapeutic and cosmeceutical applications. In: Domb AJ, Khan W, editors. Focal controlled drug delivery. Boston: Springer; 2014. pp. 535–60. [DOI]

131.

Singh N, Sondhi S, Sharma S, Singh D, Koundal V, Goyal K, et al. Treatment of skin cancer by topical drug delivery of nanoparticles: a review. Res J Pharm Technol. 2021;14:5589–98.

132.

5-fluorouracil [Internet]. Rockville (MD): National Cancer Institute; [cited 2023 Apr 12]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/5-fluorouracil

133.

Monge-Fuentes V, Muehlmann LA, de Azevedo RB. Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma. Nano Rev. 2014;5:24381. [DOI] [PubMed] [PMC]

134.

Su Y, Hu J, Huang Z, Huang Y, Peng B, Xie N, et al. Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance. Drug Des Devel Ther. 2017;11:659–68. [DOI] [PubMed] [PMC]

135.

Agarwala SS, Kirkwood JM. Temozolomide in combination with interferon α-2b in patients with metastatic melanoma. Cancer. 2003;97:121–7. [DOI] [PubMed]

136.

Jiang G, Li R, Tang J, Ma Y, Hou X, Yang C, et al. Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells. Oncol Rep. 2017;37:995–1001. [DOI] [PubMed]

137.

Pissuwan D. Monitoring and tracking metallic nanobiomaterials in vivo. In: Narayan JR, editor. Monitoring and evaluation of biomaterials and their performance in vivo. Cambridge: Woodhead Publishing; 2017. pp. 135–49.

138.

Maldonado-Camargo L, Unni M, Rinaldi C. Magnetic characterization of iron oxide nanoparticles for biomedical applications. In: Petrosko SH, Day ES, editors. Biomedical Nanotechnology. New York: Humana Press; 2017. pp. 47–71. [DOI] [PubMed] [PMC]

139.

Pearce J, Giustini A, Stigliano R, Jack Hoopes P. Magnetic heating of nanoparticles: the importance of particle clustering to achieve therapeutic temperatures. J Nanotechnol Eng Med. 2013;4:110071–14. [DOI] [PubMed] [PMC]

140.

Reddy MSB, Ponnamma D, Choudhary R, Sadasivuni KK. A comparative review of natural and synthetic biopolymer composite scaffolds. Polymers (Basel). 2021;13:1105. [DOI] [PubMed] [PMC]

141.

Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. [DOI] [PubMed] [PMC]

142.

Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3:3856–93. [DOI] [PubMed] [PMC]

143.

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15:28. [DOI] [PubMed] [PMC]

144.

Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A. 1966;55:1467–74. [DOI] [PubMed] [PMC]

145.

Smith R, Wafa EI, Geary SM, Ebeid K, Alhaj-Suliman SO, Salem AK. Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine. Sci Adv. 2022;8:eabk3150. [DOI] [PubMed] [PMC]

146.

Tran PHL, Duan W, Lee BJ, Tran TTD. Nanogels for skin cancer therapy via transdermal delivery: current designs. Curr Drug Metab. 2019;20:575–82. [DOI] [PubMed]

147.

Soni K, Mujtaba A, Akhter MH, Zafar A, Kohli K. Optimisation of ethosomal nanogel for topical nano-CUR and sulphoraphane delivery in effective skin cancer therapy. J Microencapsul. 2020;37:91–108. [DOI] [PubMed]

148.

Sahu P, Kashaw SK, Sau S, Kushwah V, Jain S, Agrawal RK, et al. pH triggered and charge attracted nanogel for simultaneous evaluation of penetration and toxicity against skin cancer: in-vitro and ex-vivo study. Int J Biol Macromol. 2019;128:740–51. [DOI] [PubMed] [PMC]

149.

Rathore S, Rajoriya V, Kushwaha V, Jain S, Kashaw SK. Preparation and characterization of 5-fluorouracil loaded nanogels for skin cancer treatments: in vitro drug release, cytotoxicity and cellular uptake analysis. Curr Nanomedicine. 2021;11:127–38. [DOI]

150.

Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, Jayakumar R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale. 2012;4:239–50. [DOI] [PubMed]

151.

Soni KS, Desale SS, Bronich TK. Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation. J Control Release. 2016;240:109–26. [DOI] [PubMed] [PMC]

152.

Abdolahinia ED, Barati G, Ranjbar-Navazi Z, Kadkhoda J, Islami M, Hashemzadeh N, et al. Application of nanogels as drug delivery systems in multicellular spheroid tumor model. J Drug Deliv Sci Technol. 2022;68:103109. [DOI]

153.

Lai WF, He ZD. Design and fabrication of hydrogel-based nanoparticulate systems for in vivo drug delivery. J Control Release. 2016;243:269–82. [DOI] [PubMed]

154.

Mauri E, Giannitelli SM, Trombetta M, Rainer A. Synthesis of nanogels: current trends and future outlook. Gels. 2021;7:36. [DOI] [PubMed] [PMC]

155.

Manimaran V, Nivetha RP, Tamilanban T, Narayanan J, Vetriselvan S, Fuloria NK, et al. Nanogels as novel drug nanocarriers for CNS drug delivery. Front Mol Biosci. 2023;10:1232109. [DOI] [PubMed] [PMC]

156.

Howaili F, Özliseli E, Küçüktürkmen B, Razavi SM, Sadeghizadeh M, Rosenholm JM. Stimuli-responsive, plasmonic nanogel for dual delivery of curcumin and photothermal therapy for cancer treatment. Front Chem. 2021;8:602941. [DOI] [PubMed] [PMC]

157.

Tran TV, Phuong THD, Tran NQ, Nguyen CK, Nguyen DH. Polymeric chitosan based nanogels as a potential platform for dual targeted drug delivery in cancer therapy. Int J Nanotechnol. 2018;15:188–98. [DOI]

158.

Liu Y, Wang M, Liu W, Jing J, Ma H. Olaparib and doxorubicin co-loaded polypeptide nanogel for enhanced breast cancer therapy. Front Bioeng Biotechnol. 2022;10:904344. [DOI] [PubMed] [PMC]

159.

Castañeda-Reyes ED, Perea-Flores MJ, Davila-Ortiz G, Lee Y, Gonzalez de Mejia E. Development, characterization and use of liposomes as amphipathic transporters of bioactive compounds for melanoma treatment and reduction of skin inflammation: a review. Int J Nanomedicine. 2020;15:7627–50. [DOI] [PubMed] [PMC]

160.

Petrilli R, Eloy JO, Saggioro FP, Chesca DL, de Souza MC, Dias MVS, et al. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release. 2018;283:151–62. [DOI] [PubMed]

161.

Gao Y, Zhang XC, Wang WS, Yang Y, Wang HL, Lu YG, et al. Efficacy and safety of topical ALA-PDT in the treatment of EMPD. Photodiagnosis Photodyn Ther. 2015;12:92–7. [DOI] [PubMed]

162.

Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK. Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes. AAPS PharmSciTech. 2018;19:166–75. [DOI] [PubMed]

163.

Saini R, Lee NV, Liu KY, Poh CF. Prospects in the application of photodynamic therapy in oral cancer and premalignant lesions. Cancers (Basel). 2016;8:83. [DOI] [PubMed] [PMC]

164.

Cadinoiu AN, Rata DM, Atanase LI, Mihai CT, Bacaita SE, Popa M. Formulations based on drug loaded aptamer-conjugated liposomes as a viable strategy for the topical treatment of basal cell carcinoma—in vitro tests. Pharmaceutics. 2021;13:866. [DOI] [PubMed] [PMC]

165.

Capecitabine or 5-FU with pegylated interferon alpha-2b in unresectable/metastatic cutaneous squamous cell carcinoma[Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 16]. Available from: https://clinicaltrials.gov/study/NCT02218164

166.

Vaccine therapy plus interleukin-2 with or without interferon alfa-2b in treating patients with stage III melanoma [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT00004104

167.

ABI-007 in treating patients with inoperable locally recurrent or metastatic melanoma [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT00081042

168.

Pharmacokinetic study of liposomal vincristine in patients with malignant melanoma & hepatic dysfunction [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT00145041

169.

Bevacizumab and temozolomide or bevacizumab and paclitaxel albumin-stabilized nanoparticle formulation and carboplatin in treating patients with stage IV malignant melanoma that cannot be removed by surgery [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT00626405

170.

A study of BIND-014 given to patients with advanced or metastatic cancer [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT01300533

171.

Nab-paclitaxel and bevacizumab or ipilimumab as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT02158520

172.

Study of topical SOR007 ointment for cutaneous metastases [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Jun 26]. Available from: https://clinicaltrials.gov/study/NCT03101358

173.

Ganguly P, Breen A, Pillai SC. Toxicity of nanomaterials: exposure, pathways, assessment, and recent advances. ACS Biomater Sci Eng. 2018;4:2237–75. [DOI] [PubMed]

174.

Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology. 2010;151:458–65. [DOI] [PubMed] [PMC]

175.

Zaiter T, Cornu R, El Basset W, Martin H, Diab M, Béduneau A. Toxicity assessment of nanoparticles in contact with the skin. J Nanopart Res. 2022;24:149. [DOI]

176.

Priyanka, Abusalah MAH, Chopra H, Sharma A, Mustafa SA, Choudhary OP, et al. Nanovaccines: a game changing approach in the fight against infectious diseases. Biomed Pharmacother. 2023;167:115597. [DOI] [PubMed]

177.

Harris TJ, Kim AAC, inventor; Coronado Aesthetics LLC, assignee. Delivery of nanoparticles. United States patent US 11419937B2. 2022 Aug 23.

178.

Harris TJ, Kim AAC, inventor; Sienna Labs Inc, assignee. Targeted delivery of nanoparticles to skin surface. World Intellectual Property Organization patent WO 2015031189A1. 2015 Mar 5.

179.

Gan L, Yong SY, Yang XL, Zhang XQ, Bie NN, inventor; Huazhong University of Science and Technology, assignee. Exosome-encapsulated nano drug delivery system for tumor treatment and preparation thereof. Chinese patent CN 108543074B. 2021 Jun 11.

180.

Wang CR, Zhou Y, Zhen MM, Bai CL, inventor; Beijing Fullcan Biotechnology Co. Ltd., assignee. Water-soluble fullerene nano material and preparation method and application thereof. Chinese patent CN 108478598B. 2021 May 7.

181.

Jang ES, Jeong AE, inventor; Kumoh National Institute of TechnologyIndustry-Academia Cooperation Foundation, assignee. Patch composition comprising graphene oxide gold nanoroad. Korean patent KR 101945112B1. 2019 Feb 1.

182.

Han SG, Jeong HS, Gong WH, Bark SE, inventor; Pohang University of Science and TechnologyIndustry-Academia Cooperation Foundation, assignee. Hyaluronic acid-carbon nano material complex and composition for photodynamic treatment comprising the same. Korean patent KR 20160003488A. 2016 Jan 11.

183.

Markovic SN, Nevala WK, inventor; Mayo Foundation for Medical Education and Research, assignee. Complexes containing albumin-containing nanoparticles and antibodies to treat cancer. Canadian patent CA 2917407C. 2023 Mar 14.

184.

Markovic SN, Nevala WK, inventor; Mayo Foundation for Medical Education and Research, assignee. Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab. United States patent US 10765741B2. 2020 Sep 8.

185.

Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018;9:1773–81. [DOI] [PubMed] [PMC]

186.

Akkın S, Varan G, Bilensoy E. A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers. Molecules. 2021;26:3382. [DOI] [PubMed] [PMC]

187.

Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73. [DOI] [PubMed] [PMC]

188.

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68. [DOI] [PubMed] [PMC]

189.

Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update post COVID-19 vaccines. BioengTransl Med. 2021;6:e10246. [DOI] [PubMed] [PMC]